Recent Publications

Bailey ML, O'Neil NJ, van Pel DM, Solomon DA, Waldman T, Hieter P. Glioblastoma Cells Containing Mutations in the Cohesin Component STAG2 Are Sensitive to PARP Inhibition. Mol Cancer Ther 13 (2014): 724-32. [PubMed] [PDF]

Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF, Elkahloun AG, Ozawa T, Gerard J, Zhuang D, Zhang S, Navai N, Siefker-Radtke A, Phillips JJ, Robinson BD, Rubin MA, Volkmer B, Hautmann R, Kufer R, Hogendoorn PCW, Netto G, Theodorescu D, James CD, Czerniak B, Miettinen M, Waldman T. Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet 45 (2013): 1428-30. [PubMed] [PDF]

Vartanian S, Bentley C, Brauer MJ, Li L, Shirasawa S, Sasazuki T, Kim JS, Haverty P, Stawiski E, Modrusan Z, Waldman T, Stokoe D. "Identification of mutant  K-Ras-dependent phenotypes using a panel of isogenic cell lines." J Biol Chem 288 (2013): 2403-13. [PubMed] [PDF]

Cen L, Carlson BL, Schroeder MA, Ostrem JL, Kitange GJ, Mladek AC, Fink SR, Decker PA, Wu W, Kim JS, Waldman T, Jenkins RB, Sarkaria JN. "p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells." Neuro Oncol 14 (2012): 870-81. [PubMed] [PDF]

Huillard E, Hashizume R, Phillips JJ, Griveau A, Ihrie RA, Aoki Y, Nicolaides T, Perry A, Waldman T, McMahon M, Weiss WA, Petritsch C, James CD, Rowitch DH. "Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy." Proc Natl Acad Sci USA 109 (2012): 8710-5. [PubMed] [PDF]

Li HF, Keeton A, Vitolo M, Maddox C, Rasmussen L, Hobrath J, White EL, Park BH, Piazza GA, Kim JS, Waldman T. "A high-throughput screen with isogenic PTEN+/+ and PTEN-/- cells identifies CID1340132 as a novel compound that induces apoptosis in PTEN and PIK3CA mutant human cancer cells." J Biomol Screen 16 (2011): 383-93. [PubMed] [PDF]

Kim JS, Xu X, Li H, Solomon D, Lane WS, Jin T, Waldman T. "Mechanistic analysis of a DNA damage-induced, PTEN-dependent size checkpoint in human cells." Mol Cell Biol 31 (2011): 2756-71. [PubMed] [PDF]

Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun AG, Harris BT, Toretsky JA, Rosenberg SA, Shukla N, Ladanyi M, Samuels Y, James CD, Yu H, Kim JS, Waldman T. "Mutational inactivation of STAG2 causes aneuploidy in human cancer." Science 333 (2011): 1039-43. [PubMed] [PDF]

Nicolaides TP, Li H, Solomon DA, Hariono S, Hashizume R, Barkovich K, Baker SJ, Paugh BS, Jones C, Forshew T, Hindley GF, Hodgson JG, Kim JS, Rowitch DH, Weiss WA, Waldman T, James CD. "Targeted therapy for BRAFV600E malignant astrocytoma." Clin Cancer Res 17 (2011): 7595-604.[PubMed] [PDF]

Michaud K, Solomon DA, Oermann E, Kim JS, Zhong WZ, Prados MD, Ozawa T, James D, Waldman T. "Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts." Cancer Res 70 (2010): 3228-3238. [PubMed] [PDF]

Solomon DA, Kim JS, Ressom HW, Sibenaller Z, Ryken T, Jean W, Bigner D, Yan H, Waldman T. "Sample type bias in the analysis of cancer genomes." Cancer Res 69 (2009): 5630-5633. [PubMed] [PDF]

Li HF, Kim JS, Waldman T. "Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells." Radiat Oncol 4 (2009). [PubMed] [PDF]

Vitolo MI, Weiss MB, Szmacinski M, Tahir K, Waldman T, Park BH, Martin SS, Weber DJ, Bachman KE. "Deletion of PTEN promotes tumorigenic signaling, resistance to anoikis, and altered response to chemotherapeutic agents in human mammary epithelial cells." Cancer Res 69 (2009): 8275-8283. [PubMed] [PDF]

Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, Waldman T, Lord CJ, Ashworth A. "Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors." EMBO Mol Med 1 (2009): 315-322. [PubMed] [PDF]

Solomon D, Kim JS, Cronin J, Sibenaller Z, Ryken T, Rosenberg S, Ressom H, Jean W, Bigner D, Yan H, Samuels Y, Waldman T. "Mutational Inactivation of PTPRD in Glioblastoma Multiforme and Malignant Melanoma." Cancer Res 68 (2008): 10300-10306. [PubMed] [PDF]

Kim JS, Bonifant C, Bunz F, Lane WS, Waldman T. "Epitope Tagging of Endogenous Genes in Human Cells." Nucleic Acids Res 36 (2008): e127. [PubMed] [PDF]

Solomon D, Kim JS, Jean W, Waldman T. "Conspirators in a Capital Crime: Co-Deletion of p18INK4c andp16INK4a/p14ARF/p15INK4b in Glioblastoma Multiforme." Cancer Res 68 (2008): 8657-8660. [PubMed] [PDF]

Solomon D, Kim JS, Jenkins S, Jean W, Bigner D, Yan H, Waldman T. "Identification of p18INK4c as a Tumor Suppressor Gene in Glioblastoma Multiforme." Cancer Res 68 (2008): 2564-2569. [PubMed] [PDF]

Bonifant CL, Kim JS, Waldman T. “NHERFs, NEP, MAGUKs, and more: Interactions that regulate PTEN.” J Cell Biochem 102 (2007): 878-85. [PubMed] [PDF]

Kim JS, Lee C, Bonifant CL, Ressom H, Waldman T. “Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.” Mol Cell Biol 27 (2007): 662-77. [PubMed] [PDF]

Lee C, Kim JS, Waldman T. “PTEN gene targeting reveals a radiation-induced size checkpoint in human cancer cells.” Cancer Res 64 (2004): 6906-14. [PubMed] [PDF]

Kim JS, Lee C, Foxworth A, Waldman T. “B-Raf is dispensable for K-Ras-mediated oncogenesis in human cancer cells.” Cancer Res 64 (2004): 1932-7. [PubMed] [PDF]

Kim JS, Crooks H, Dracheva T, Nishanian TG, Singh B, Jen J, Waldman T. “Oncogenic beta-catenin is required for bone morphogenetic protein 4 expression in human cancer cells.” Cancer Res 62 (2002): 2744-8. [PubMed] [PDF]

Kim JS, Crooks H, Foxworth A, Waldman T. “Proof-of-principle: oncogenic beta-catenin is a valid molecular target for the development of pharmacological inhibitors.” Mol Cancer Ther 14 (2002): 1355-9. [PubMed] [PDF]